OtherClinical Investigations (Human)
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A. O'Donoghue, Shutian Ruan, Serge Lyashchenko, Jorge A. Carrasquillo, Glen Heller, Danny F. Martinez, Sarah M. Cheal, Jason S. Lewis, Martin Fleisher, Jennifer S. Keppler, Robert E. Reiter, Anna M. Wu, Wolfgang A. Weber, Howard I. Scher, Steven M. Larson and Michael J. Morris
Journal of Nuclear Medicine August 2016, jnumed.116.176206; DOI: https://doi.org/10.2967/jnumed.116.176206
Neeta Pandit-Taskar
1 Memorial Sloan Kettering Cancer Center, United States;
Joseph A. O'Donoghue
1 Memorial Sloan Kettering Cancer Center, United States;
Shutian Ruan
1 Memorial Sloan Kettering Cancer Center, United States;
Serge Lyashchenko
1 Memorial Sloan Kettering Cancer Center, United States;
Jorge A. Carrasquillo
1 Memorial Sloan Kettering Cancer Center, United States;
Glen Heller
1 Memorial Sloan Kettering Cancer Center, United States;
Danny F. Martinez
1 Memorial Sloan Kettering Cancer Center, United States;
Sarah M. Cheal
1 Memorial Sloan Kettering Cancer Center, United States;
Jason S. Lewis
1 Memorial Sloan Kettering Cancer Center, United States;
Martin Fleisher
1 Memorial Sloan Kettering Cancer Center, United States;
Jennifer S. Keppler
2 ImaginAb, Inc., United States
Robert E. Reiter
2 ImaginAb, Inc., United States
Anna M. Wu
2 ImaginAb, Inc., United States
Wolfgang A. Weber
1 Memorial Sloan Kettering Cancer Center, United States;
Howard I. Scher
1 Memorial Sloan Kettering Cancer Center, United States;
Steven M. Larson
1 Memorial Sloan Kettering Cancer Center, United States;
Michael J. Morris
1 Memorial Sloan Kettering Cancer Center, United States;
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 3
March 1, 2024
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A. O'Donoghue, Shutian Ruan, Serge Lyashchenko, Jorge A. Carrasquillo, Glen Heller, Danny F. Martinez, Sarah M. Cheal, Jason S. Lewis, Martin Fleisher, Jennifer S. Keppler, Robert E. Reiter, Anna M. Wu, Wolfgang A. Weber, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal of Nuclear Medicine Aug 2016, jnumed.116.176206; DOI: 10.2967/jnumed.116.176206
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A. O'Donoghue, Shutian Ruan, Serge Lyashchenko, Jorge A. Carrasquillo, Glen Heller, Danny F. Martinez, Sarah M. Cheal, Jason S. Lewis, Martin Fleisher, Jennifer S. Keppler, Robert E. Reiter, Anna M. Wu, Wolfgang A. Weber, Howard I. Scher, Steven M. Larson, Michael J. Morris
Journal of Nuclear Medicine Aug 2016, jnumed.116.176206; DOI: 10.2967/jnumed.116.176206
Jump to section
Related Articles
Cited By...
- Antibody Engineering for Nuclear Imaging and Radioimmunotherapy
- CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
- 11C Dosimetry Scans Should Be Abandoned
- Effect of Modulating FcRn Binding on Direct and Pretargeted Tumor Uptake of Full-length Antibodies
- First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
- Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
- A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
- Immune Modulation Therapy and Imaging: Workshop Report
- Long-Half-Life 89Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer
- Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer
- Targeted {alpha}-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding